• Stock Symbol  ASX:VLA
  • Company Type For Profit
  • Contact Email investorrelations@viralytics.com
  • Phone Number +61 2 9988 4000

Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market (VRACY). Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics' headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia.

Oncolytic virotherapy makes use of the cancer destroying capabilities of a range of benign viruses. The potential of oncolytic virotherapy is the ability to treat cancers more effectively and with minimum side-effects.

Lists Featuring This Company

Australia Companies With Fewer Than 50 Employees (Top 10K)
9,868 Number of Organizations â€¢ $19B Total Funding Amount â€¢ 4,997 Number of Investors
Sydney Health Care Companies
769 Number of Organizations â€¢ $1.7B Total Funding Amount â€¢ 171 Number of Investors
New South Wales Companies With More Than 10 Employees (Top 10K)
9,392 Number of Organizations â€¢ $59.8B Total Funding Amount â€¢ 2,692 Number of Investors
Sydney Companies With Fewer Than 1000 Employees (Top 10K)
9,759 Number of Organizations â€¢ $33.6B Total Funding Amount â€¢ 2,831 Number of Investors
Viralytics was acquired by Merck for A$502M on Feb 21, 2018.

Frequently Asked Questions

Where is Viralytics's headquarters? Viralytics is located in Sydney, New South Wales, Australia.How much funding has Viralytics raised to date? Viralytics has raised .When was the last funding round for Viralytics? Viralytics closed its last funding round on Mar 13, 2014 from a Post-IPO Equity round.Who are Viralytics's competitors? Alternatives and possible competitors to Viralytics may include Inovio PharmaceuticalsCedilla Therapeutics, and Innovative Cellular Therapeutics.